NCT07134998View on ClinicalTrials.gov

Phase I Study of HRS-6093 in Participants With Advanced Solid Tumors Harboring KRAS G12D Mutations

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

153

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

May 31, 2028

Study Completion Date

December 31, 2028

Conditions

Advanced KRAS G12D Mutant Solid Tumors

Interventions

DRUG

HRS-6093

HRS-6093

Trial Locations (1)

200025

Shanghai Jiao Tong University School of Medicine, Shanghai

All Listed Sponsors

lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY